| Ident. | Authors (with country if any) | Title |
|---|
| 000120 |
Ashley H. Spencer [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Alfonso Fasano [Italie] ; Andrea E. Cavanna [Royaume-Uni] | The prevalence and clinical characteristics of punding in Parkinson's disease |
| 000159 |
Keisuke Matsubara [Japon] ; Hiroshi Watabe [Japon] ; Yoshitaka Kumakura [Japon] ; Takuya Hayashi [Japon] ; Christopher J. Endres [États-Unis] ; Kotaro Minato [Japon] ; Hidehiro Iida [Japon] | Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: A simulation study for [18F]FDOPA PET by a model with detailed dopamine pathway |
| 000167 |
Dimitrios Kapogiannis [États-Unis] ; Eric Mooshagian [États-Unis] ; Paul Campion [États-Unis] ; Jordan Grafman [États-Unis] ; Trelawny J. Zimmermann [États-Unis] ; Kelsey C. Ladt [États-Unis] ; Eric M. Wassermann [États-Unis] | Reward processing abnormalities in Parkinson's disease |
| 000182 |
Natalie R. S. Goldberg [États-Unis] ; Tom Hampton [États-Unis] ; Scott Mccue [États-Unis] ; Ajit Kale [États-Unis] ; Charles K. Meshul [États-Unis] | Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning |
| 000230 |
Lucia Frau [Italie] ; Franco Borsini [Italie] ; Jadwiga Wardas [Pologne] ; Amit S. Khairnar [Italie] ; Nicoletta Schintu [Italie] ; Micaela Morelli [Italie] | Neuroprotective and anti‐inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease |
| 000247 |
A. Jon Stoessl [Canada] ; David J. Brooks [Royaume-Uni] ; David Eidelberg [États-Unis] | Milestones in neuroimaging |
| 000320 |
T. Archer [Suède] ; A. Fredriksson [Suède] ; B. Johansson [Suède] | Exercise alleviates Parkinsonism: clinical and laboratory evidence |
| 000337 |
Thomas D. H Lbig [États-Unis, Allemagne] ; Stephanie Assuras [États-Unis] ; Judy Creighton [États-Unis] ; Joan C. Borod [États-Unis] ; Winona Tse [États-Unis] ; Pasquale G. Frisina [États-Unis] ; Andrei Voustianiouk [États-Unis] ; Jean-Michel Gracies [États-Unis] ; C. Warren Olanow [États-Unis] | Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease |
| 000374 |
D. S. Goldstein [États-Unis] ; P. Sullivan [États-Unis] ; C. Holmes [États-Unis] ; I. J. Kopin [États-Unis] ; M. J. Basile [États-Unis] ; D. C. Mash [États-Unis] | Catechols in post‐mortem brain of patients with Parkinson disease |
| 000393 |
Danielle M. Shore ; Robert Rafal ; John A. Parkinson | Appetitive motivational deficits in individuals with Parkinson's Disease |
| 000702 |
Aleksandra Glavaski-Joksimovic [États-Unis] ; Tamas Virag [États-Unis] ; Thomas A. Mangatu [États-Unis] ; Michael Mcgrogan [États-Unis] ; Xue Song Wang [États-Unis] ; Martha C. Bohn [États-Unis] | Glial cell line‐derived neurotrophic factor–secreting genetically modified human bone marrow‐derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease |
| 000706 |
Tomas Bjorklund [Suède] ; Jeffrey H. Kordower [États-Unis] | Gene therapy for Parkinson's disease |
| 000734 |
Ruth H. Walker [États-Unis] ; Georgia Davies [États-Unis] ; Rick J. Koch [États-Unis] ; Andrew K. Haack [États-Unis] ; Cynthia Moore [États-Unis] ; Charles K. Meshul [États-Unis] | Effects of zona incerta lesions on striatal neurochemistry and behavioral asymmetry in 6‐hydroxydopamine‐lesioned rats |
| 000741 |
David Devos [France] ; L. Defebvre [France] ; R. Bordet [France] | Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease |
| 000809 |
Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni] | Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? |
| 000840 |
C. Savio Chan [États-Unis] ; Tracy S. Gertler [États-Unis] ; D. James Surmeier [États-Unis] | A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease |
| 000A48 |
A. H. V. Schapira [Royaume-Uni] ; M. Emre [Turquie] ; P. Jenner [Royaume-Uni] ; Werner Poewe [Autriche] | Levodopa in the treatment of Parkinson’s disease |
| 000A87 |
Ji E. Lee [Corée du Sud] ; Hae-Won Shin [Corée du Sud] ; Kyung S. Kim [Corée du Sud] ; Young H. Sohn [Corée du Sud] | Factors contributing to the development of restless legs syndrome in patients with Parkinson disease |
| 000B25 |
Tultul Nayyar [États-Unis] ; Michael Bubser [États-Unis] ; Marcus C. Ferguson [États-Unis] ; M. Diana Neely [États-Unis] ; J. Shawn Goodwin [États-Unis] ; Thomas J. Montine [États-Unis] ; Ariel Y. Deutch [États-Unis] ; Twum A. Ansah [États-Unis] | Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation |
| 000B32 |
Gabriel Robert [France] ; Dominique Drapier [France] ; Marc Verin [France] ; Bruno Millet [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology |
| 000C94 |
Eleonora Bazzini [Italie] ; Alberta Samuele [Italie] ; Marcella Granelli [Italie] ; Giovanna Levandis [Italie] ; Marie-Therese Armentero [Italie] ; Giuseppe Nappi [Italie] ; Fabio Blandini [Italie] | Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine |
| 000F78 |
Yuji Nagai [Japon] ; Shigeru Obayashi [Japon] ; Kiyoshi Ando [Japon] ; Motoki Inaji [Japon] ; Jun Maeda [Japon] ; Takashi Okauchi [Japon] ; Hiroshi Ito [Japon] ; Tetsuya Suhara [Japon] | Progressive changes of pre‐ and post‐synaptic dopaminergic biomarkers in conscious MPTP‐treated cynomolgus monkeys measured by positronemission tomography |
| 000F84 |
Andrew J. Lawrence [Royaume-Uni] ; Andrew D. Blackwell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Francesca Spagnolo [Italie] ; Luke Clark [Royaume-Uni] ; Michael R. F. Aitken [Royaume-Uni] ; Barbara J. Sahakian [Royaume-Uni] | Predictors of punding in Parkinson's disease: Results from a questionnaire survey |
| 000F89 |
Chen [États-Unis] ; Swope [États-Unis] | Pharmacotherapy for Parkinson's Disease |
| 001040 |
Emilie Lacombe ; Carole Carcenac ; Sabrina Boulet ; Claude Feuerstein [France] ; Anne Bertrand ; Annie Poupard ; Marc Savasta [France] | High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated rats |
| 001124 |
Annalisa Pinna [Italie] ; Silvia Pontis [Italie] ; Franco Borsini [Italie] ; Micaela Morelli [Italie] | Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease |
| 001245 |
Plamen Gatev [États-Unis] ; Olivier Darbin [États-Unis] ; Thomas Wichmann [États-Unis] | Oscillations in the basal ganglia under normal conditions and in movement disorders |
| 001254 |
David W. Anderson [États-Unis] ; Kristin A. Bradbury [États-Unis] ; Jay S. Schneider [États-Unis] | Neuroprotection in Parkinson models varies with toxin administration protocol |
| 001325 |
A. Lieberman [États-Unis] | Depression in Parkinson's disease – a review |
| 001362 |
Rebecca E. Colebrooke [Royaume-Uni] ; Trevor Humby [Royaume-Uni] ; Patrick J. Lynch [Royaume-Uni] ; Daniel P. Mcgowan [Royaume-Uni] ; Jing Xia [Royaume-Uni] ; Piers C. Emson [Royaume-Uni] | Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease |
| 001492 |
M. Mishina [Japon] ; K. Ishiwata [Japon] ; K. Ishii [Japon] ; S. Kitamura [Japon] ; Y. Kimura [Japon] ; K. Kawamura [Japon] ; K. Oda [Japon] ; T. Sasaki [Japon] ; O. Sakayori [Japon] ; M. Hamamoto [Japon] ; S. Kobayashi [Japon] ; Y. Katayama [Japon] | Function of sigma1 receptors in Parkinson's disease |
| 001527 |
J. Eric Ahlskog [États-Unis] | Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease |
| 001539 |
Guowei Huang [Canada, République populaire de Chine] ; Magdalena Dragan [Canada] ; David Freeman [Canada] ; John X. Wilson [Canada, États-Unis] | Activation of catechol‐O‐methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons |
| 001603 |
Dina Ruano [Portugal] ; Ant Nio Macedo [Portugal] ; Ana Dourado [Portugal] ; Maria João Soares [Portugal] ; José Valente [Portugal] ; Isabel Coelho [Portugal] ; Vítor Santos [Portugal] ; Maria Helena Azevedo [Portugal] ; Ann Goodman [États-Unis] ; Mara Helena Hutz [Brésil] ; Clarissa Gama [Brésil] ; Maria Inês Lobato [Brésil] ; Paulo Belmonte-De-Abreu [Brésil] ; Joana Almeida Palha [Portugal] | NR4A2 and schizophrenia: Lack of association in a Portuguese/Brazilian study |
| 001653 |
Mathias Pessiglione [France] ; Dominique Guehl [France] ; Caroline Jan [France] ; Chantal François [France] ; Etienne C. Hirsch [France] ; Jean Féger [France] ; Léon Tremblay [France] | Disruption of self‐organized actions in monkeys with progressive MPTP‐induced parkinsonism: II. Effects of reward preference |
| 001672 |
Sylvia M. Boesch [Autriche] ; Eveline Donnemiller [Autriche] ; Jörg Müller [Autriche] ; Klaus Seppi [Autriche] ; Helga Weirich-Schwaiger [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Abnormalities of dopaminergic neurotransmission in SCA2: A combined 123I‐βCIT and 123I‐IBZM SPECT study |
| 001676 |
Evelien Huisman [Pays-Bas] ; Harry B. M. Uylings [Pays-Bas] ; Piet V. Hoogland [Pays-Bas, Afrique du Sud] | A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease |
| 001740 |
Andrea Carmine [Suède] ; Silvia Buervenich [Suède] ; Dagmar Galter [Suède] ; Erik G. Jönsson [Suède] ; Göran C. Sedvall [Suède] ; Lars Farde [Suède] ; J. Petter Gustavsson [Suède] ; Hans Bergman [Suède] ; Kodavali V. Chowdari [États-Unis] ; Vishwajit L. Nimgaonkar [États-Unis] ; Maria Anvret [Suède] ; Olof Sydow [Suède] ; Lars Olson [Suède] | NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits |
| 001759 |
Yassine Darbaky [France] ; Claude Forni [France] ; Marianne Amalric [France] ; Christelle Baunez [France] | High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task |
| 001789 |
Stanley Fahn [États-Unis] | Description of Parkinson's Disease as a Clinical Syndrome |
| 001844 |
Joseph O'Neill [États-Unis] ; Norbert Schuff [États-Unis] ; William J. Marks Jr. [États-Unis] ; Robert Feiwell [États-Unis] ; Michael J. Aminoff [États-Unis] ; Michael W. Weiner [États-Unis] | Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease |
| 001862 |
J. Finsterer [Autriche] | Parkinson syndrome as a manifestation of mitochondriopathy |
| 001999 |
David S. Rothblat [États-Unis] ; J. A. Schroeder [États-Unis] ; J. S. Schneider [États-Unis] | Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: Potential contributors to spontaneous recovery from experimental Parkinsonism |
| 001A12 |
Gustavo A. Carvalho [Allemagne] ; Guido Nikkhah [Allemagne] | Subthalamic Nucleus Lesions Are Neuroprotective against Terminal 6-OHDA-Induced Striatal Lesions and Restore Postural Balancing Reactions |
| 001A17 |
Diana Frechilla [Espagne] ; Almudena Cobreros [Espagne] ; Laura Saldise [Espagne] ; Rosario Moratalla [Espagne] ; Ricardo Insausti [Espagne] ; M-Rosario Luquin [Espagne] ; Joaquín Del Río [Espagne] | Serotonin 5‐HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys |
| 001A20 |
Jane R. Taylor [États-Unis] ; J. David Jentsch [États-Unis] | Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d -amphetamine and 3,4-methylenedioxymethamphetamine (“ecstasy”) |
| 001A55 |
Rosario Sánchez-Pernaute [États-Unis] ; Lorenz Studer [États-Unis] ; Krys S. Bankiewicz [États-Unis] ; Eugene O. Major [États-Unis] ; Ronald D. G. Mckay [États-Unis] | In vitro generation and transplantation of precursor‐derived human dopamine neurons |
| 001A57 |
Silvia Buervenich [Suède] ; Fengqing Xiang [Suède] ; Olof Sydow [Suède] ; Erik G. Jönsson [Suède] ; Göran C. Sedvall [Suède] ; Maria Anvret [Suède] ; Lars Olson [Suède] | Identification of four novel polymorphisms in the calcitonin/α‐CGRP (CALCA) gene and an investigation of their possible associations with Parkinson disease, schizophrenia, and manic depression |
| 001A89 |
S. Thobois [France] ; S. Guillouet [France] ; E. Broussolle [France] | Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease |
| 001A91 |
Alexandra Roedter [Allemagne] ; Christian Winkler [Allemagne] ; Madjid Samii [Allemagne] ; Gerhard F. Walter [Allemagne] ; Almuth Brandis [Allemagne] ; Guido Nikkhah [Allemagne] | Comparison of unilateral and bilateral intrastriatal 6‐hydroxydopamine‐induced axon terminal lesions: Evidence for interhemispheric functional coupling of the two nigrostriatal pathways |
| 001B69 |
Sophie Callier [Canada, France] ; Marc Morissette [Canada] ; Michelle Grbois [Canada] ; Thérèse Di Paolo [Canada] | Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice |
| 001B92 |
Yi Zhang ; Valina L. Dawson ; Ted M. Dawson | Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease |
| 001C05 |
I. Lamensdorf [États-Unis] ; G. Eisenhofer [États-Unis] ; J. Harvey-White [États-Unis] ; Y. Hayakawa [États-Unis] ; K. Kirk [États-Unis] ; I. J. Kopin [États-Unis] | Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4‐dihydroxyphenylacetaldehyde |
| 001C52 |
F. G Kaddis [États-Unis] ; E. D Clarkson [États-Unis] ; K. P Bell [États-Unis] ; P. K Choi [États-Unis] ; C. R Freed [États-Unis] | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| 001C61 |
Oleg V. Anichtchik [Finlande] ; Juha O. Rinne [Finlande] ; Hannu Kalimo [Finlande] ; Pertti Panula [Finlande] | An Altered Histaminergic Innervation of the Substantia Nigra in Parkinson's Disease |
| 001D25 |
P. Damier ; E. C. Hirsch ; Yves Agid [France] ; A. M. Graybiel | The substantia nigra of the human brain |
| 001D42 |
Claas Bentlage [Suède] ; Guido Nikkhah [Suède] ; Miles G. Cunningham [États-Unis] ; Anders Björklund [Suède] | Reformation of the Nigrostriatal Pathway by Fetal Dopaminergic Micrografts into the Substantia Nigra Is Critically Dependent on the Age of the Host |
| 001D61 |
Martin Goulet ; Marc Morissette ; Richard Grondin ; Pierre Falardeau ; Paul J. Bédard ; William Rostène [France] ; Thérèse Di Paolo | Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys |
| 001D65 |
C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni] | Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum |
| 001D75 |
Christian Winkler [Suède] ; Claas Bentlage [Allemagne] ; Guido Nikkhah [Allemagne] ; Madjid Samii [Allemagne] ; Anders Björklund [Suède] | Intranigral Transplants of GABA-Rich Striatal Tissue Induce Behavioral Recovery in the Rat Parkinson Model and Promote the Effects Obtained by Intrastriatal Dopaminergic Transplants |
| 001E55 |
C. S. Biggs [Royaume-Uni] ; A. Fisher [Royaume-Uni] ; M. S. Starr [Royaume-Uni] | The antiparkinsonian drug budipine stimulates the activity of aromatic L‐amino acid decarboxylase and enhances L‐DOPA‐induced dopamine release in rat substantia nigra |
| 001F23 |
Dominic B. Rowe [États-Unis] ; Weidong Le [États-Unis] ; R. Glenn Smith [États-Unis] ; Stanley H. Appel [États-Unis] | Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation |
| 002155 |
S. Hunot [France] ; F. Boissière [France] ; B. Faucheux [France] ; B. Brugg [France] ; A. Mouatt-Prigent [France] ; Yves Agid [France] ; E. C. Hirsch [France] | Nitric oxide synthase and neuronal vulnerability in parkinson's disease |
| 002167 |
A. Mouatt-Prigent [France] ; J. O. Karlsson [Suède] ; Yves Agid [France] ; E. C. Hirsch [France] | Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? |
| 002204 |
W. Löscher [Allemagne] ; A. Richter [Allemagne] ; G. Nikkhah [Allemagne] ; C. Rosenthal [Allemagne] ; U. Ebert [Allemagne] ; H.-J. Hedrich [Allemagne] | Behavioural and neurochemical dysfunction in the circling (ci) rat: A novel genetic animal model of a movement disorder |
| 002518 |
G. Nikkhah [Suède] ; W.-M. Duan [Suède] ; U. Knappe [Allemagne] ; A. Jo Dicke [Allemagne] ; A. Bjo Rklund [Suède] | Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat parkinson model |
| 002551 |
G. Masson [France] ; D. Mestre [France] ; O. Blin [France] | Dopaminergic modulation of visual sensitivity in man |
| 002553 |
Aj Lees [Royaume-Uni] | Dopamine agonists in Parkinson's disease: a look at apomorphine |
| 002682 |
H. Allain [France] ; J. Cougnard [France] ; H-C. Neukirch [France] | Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT) |
| 002694 |
J. S. Schneider [États-Unis] ; D. S. Rothblat [États-Unis] | Neurochemical evaluation of the striatum in symptomatic and recovered mptp-treated cats |
| 002816 |
O. Lindvall [Suède] ; A. Björklund [Suède] | Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials |
| 002817 |
I. C. Dissing [Danemark] ; F. Güttler [Danemark] ; H. Pakkenberg [Danemark] ; H. Lou [Danemark] ; A. Gerdes [Danemark] ; C. Lykkelund [Danemark] ; V. Rasmussen [Danemark] | Tetrahydrobiopterin and Parkinson's disease |
| 002A78 |
Bernard Scatton ; France Javoy-Agid [France] ; Liliane Rouquier ; Bruno Dubois [France] ; Yves Agid [France] | Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease |
